Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NONO_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NONO_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NONO_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NONO_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NONO_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NONO_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NONO_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NONO_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003647319 | Oral cavity | OSCC | cell death in response to oxidative stress | 52/7305 | 95/18723 | 1.33e-03 | 6.62e-03 | 52 |
GO:00022184 | Oral cavity | OSCC | activation of innate immune response | 31/7305 | 52/18723 | 2.08e-03 | 9.59e-03 | 31 |
GO:190040718 | Oral cavity | OSCC | regulation of cellular response to oxidative stress | 47/7305 | 89/18723 | 5.62e-03 | 2.17e-02 | 47 |
GO:190320118 | Oral cavity | OSCC | regulation of oxidative stress-induced cell death | 40/7305 | 74/18723 | 6.09e-03 | 2.30e-02 | 40 |
GO:003647510 | Oral cavity | OSCC | neuron death in response to oxidative stress | 19/7305 | 31/18723 | 9.93e-03 | 3.48e-02 | 19 |
GO:190320310 | Oral cavity | OSCC | regulation of oxidative stress-induced neuron death | 17/7305 | 27/18723 | 1.01e-02 | 3.49e-02 | 17 |
GO:190288218 | Oral cavity | OSCC | regulation of response to oxidative stress | 50/7305 | 98/18723 | 1.03e-02 | 3.53e-02 | 50 |
GO:00313495 | Oral cavity | OSCC | positive regulation of defense response | 127/7305 | 278/18723 | 1.32e-02 | 4.39e-02 | 127 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:0097193110 | Oral cavity | LP | intrinsic apoptotic signaling pathway | 146/4623 | 288/18723 | 9.76e-22 | 2.78e-19 | 146 |
GO:2001233110 | Oral cavity | LP | regulation of apoptotic signaling pathway | 168/4623 | 356/18723 | 1.35e-20 | 3.02e-18 | 168 |
GO:2001242110 | Oral cavity | LP | regulation of intrinsic apoptotic signaling pathway | 95/4623 | 164/18723 | 9.85e-20 | 1.99e-17 | 95 |
GO:0006979110 | Oral cavity | LP | response to oxidative stress | 181/4623 | 446/18723 | 5.74e-14 | 6.10e-12 | 181 |
GO:2001243110 | Oral cavity | LP | negative regulation of intrinsic apoptotic signaling pathway | 56/4623 | 98/18723 | 6.93e-12 | 5.48e-10 | 56 |
GO:2001234110 | Oral cavity | LP | negative regulation of apoptotic signaling pathway | 102/4623 | 224/18723 | 7.22e-12 | 5.58e-10 | 102 |
GO:0062197110 | Oral cavity | LP | cellular response to chemical stress | 130/4623 | 337/18723 | 8.94e-09 | 3.52e-07 | 130 |
GO:0070997110 | Oral cavity | LP | neuron death | 135/4623 | 361/18723 | 4.31e-08 | 1.52e-06 | 135 |
GO:0034599110 | Oral cavity | LP | cellular response to oxidative stress | 110/4623 | 288/18723 | 2.19e-07 | 6.65e-06 | 110 |
GO:1901214110 | Oral cavity | LP | regulation of neuron death | 115/4623 | 319/18723 | 3.39e-06 | 7.19e-05 | 115 |
GO:005140218 | Oral cavity | LP | neuron apoptotic process | 91/4623 | 246/18723 | 1.07e-05 | 1.94e-04 | 91 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NONO | SNV | Missense_Mutation | | c.292N>A | p.Gly98Arg | p.G98R | Q15233 | protein_coding | deleterious(0.01) | possibly_damaging(0.768) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NONO | SNV | Missense_Mutation | | c.911N>A | p.Arg304His | p.R304H | Q15233 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD |
NONO | SNV | Missense_Mutation | novel | c.1081G>A | p.Glu361Lys | p.E361K | Q15233 | protein_coding | deleterious(0) | possibly_damaging(0.587) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NONO | insertion | Frame_Shift_Ins | novel | c.853_854insA | p.Val285AspfsTer10 | p.V285Dfs*10 | Q15233 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
NONO | insertion | In_Frame_Ins | novel | c.854_855insCTC | p.Val285_Asp286insSer | p.V285_D286insS | Q15233 | protein_coding | | | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
NONO | insertion | Frame_Shift_Ins | novel | c.1405_1406insACTTTAAGGGGGTGACATATATGTCTTACTTA | p.Arg469HisfsTer26 | p.R469Hfs*26 | Q15233 | protein_coding | | | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
NONO | deletion | Frame_Shift_Del | | c.1268delG | p.Gly423GlufsTer5 | p.G423Efs*5 | Q15233 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
NONO | SNV | Missense_Mutation | novel | c.523N>C | p.Glu175Gln | p.E175Q | Q15233 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
NONO | SNV | Missense_Mutation | novel | c.265N>A | p.Glu89Lys | p.E89K | Q15233 | protein_coding | deleterious(0) | benign(0.021) | TCGA-EX-A8YF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
NONO | SNV | Missense_Mutation | | c.694N>C | p.Asp232His | p.D232H | Q15233 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |